Boston Scientific Receives European Regulatory Approval For New Precision Spectra™ Spinal Cord Stimulator System

Boston Scientific Receives European Regulatory Approval For New Precision Spectra™ Spinal Cord Stimulator System PR Newswire NATICK, Massachusetts, Dec. 7, 2012 -- World's First and Only System with 32 Contacts and 32 Dedicated Power Sources is Designed to Provide Pain Relief to a Broad Spectrum of Chronic Pain Patients NATICK, Massachusetts, Dec. 7, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval and has begun the European market launch of the Precision Spectra™ Spinal Cord Stimulator (SCS) System. The Precision Spectra System is the world's first and only SCS system with 32 contacts and 32 dedicated power sources and is designed to provide improved pain relief to a wide range of patients who suffer from chronic pain. The first commercial implant of the Precision Spectra System was performed last month by Dr. Simon Thomson, Consultant in Pain Medicine and Neuromodulation, at the Basildon and Thurrock University Hospitals in the United Kingdom. Chronic pain affects one in five adults in Europe, or about 95 million people 15 to 64 years of age. Living in constant pain for an extended period of time can have a devastating impact on quality of life for many patients. Without relief, or the hope for relief, many patients lose the ability to sleep, work and function normally. Designed to manage chronic pain, spinal cord stimulators deliver electrical pulses from an implantable pulse generator to leads with stimulating contacts.